The DISSECT Study: Effect of Peri-aDventItial SMA diSsECtion on Margin sTatus During Pancreaticoduodenectomy for Resectable Pancreatic Cancer
NCT ID: NCT04902352
Last Updated: 2025-11-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
102 participants
INTERVENTIONAL
2021-04-06
2026-10-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The goal of this randomised controlled trial is to investigate the role of routine peri-adventitial dissection on the SMA margin status.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Hepatic Resection for Metastatic Pancreatic Cancer
NCT02892305
Pancreatoduodenectomy With Mesopancreas Dissection.A Prospective Study Comparing Artery-first Approach Versus Standard Approach
NCT03224832
Survival Among Patients With Pancreatic Cancer Depending on Surgical Resection Rate
NCT04802993
Perioperative Cancer Cell Dissemination and Systemic Immune Suppression in Resectable Ductal Pancreatic Adenocarcinoma
NCT00495924
Cohort Study on Nutritional, Metabolic, and Volumetric Assessment After Pancreaticoduodenectomy
NCT07159672
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The SMA margin is positive in 47-77% of these resections, even when the margin is "clear" on the pre-operative staging CT2,4. Many different techniques are in practice and have been described for this part of the pancreaticoduodenectomy procedure, including the use of diathermy and ties, energy devices such as Ligasure, and staplers. The main denominator is staying close to the SMA and removing the so called "mesopancreas"3.Peri-adventitial arterial dissection is a technique that has been a commune practise in several pancreatic centres and has been proposed as an effective surgical technique to achieve R0 margins. On the other hand, SMA dissection may theoretically increase the risk of acute haemorrhage, vascular injury, and thrombosis, development of pseudo-aneurysms or persistent chyle leak due to the extensive lymphoneural dissection. Furthermore, the published evidence reveal variability in the definition of a "positive margin", as well as the lack of accurate description of the surgical technique in the majority of the studies, with only about 25% of the studies reporting the use of the technique4. Moreover, none of the published studies have documented standardisation in the use of the technique with regards to the extent of the periadventitial dissection on the SMA, longitudinally and circumferentially.
In the University Hospitals of Birmingham NHS Trust, pancreatic surgery is centralised in Queen Elizabeth Hospital. Peri-adventitial dissection is selectively performed in cases where there is a close relation of the tumour to the arteries in an effort to achieve an R0 resection. Routine practice of peri-adventitial dissection during pancreaticoduodenectomy for resectable tumours has been performed in a subset of patients based on surgeon's preference. The results suggest a R1 rate of 20%, with SMA margin positivity 5%, compared to a rate of 44% margin positivity within the unit, with 54% SMA R1 rate. Furthermore, complication rates are comparable to the average described by the unit's results and published literature (20.8% of grade B and above complications as per the Clavien-Dindo classification). More specifically, there have been no incidences of vascular related injury or complication related to the technique; or persistent chyle leak (one episode of chyle leak grade A recorded that was managed conservatively).
The goal of this prospective study is to investigate the role of routine peri-adventitial dissection on the SMA margin status. Primary outcome is SMA margin status. Secondary outcomes are: length of stay, complications, overall survival, disease free survival and adjuvant treatment uptake.
This will be a two arm, randomised 1:1 (periadventitial dissection : no periadventitial dissection) study. A pilot phase will determine feasibility to proceed with the rest of the trial and to determine:
1. Feasibility of patient recruiting and randomisation
2. Feasibility and reproducibility of the technique
3. Feasibility of use of intraoperative photography
4. Intraoperative and postoperative complication rate and severity (Clavien-Dindo classification)
5. Positive SMA margin status rate
Feasibility criteria to be met in order to proceed with the rest of the trial:
6. Recruitment of at least 20 patients in 6 months (both arms)
7. Periadventitial dissection technique to be performed in at least 80% of the randomised patients to that arm as documented by intraoperative photography
8. Increase in the complication rate no more than 10%
For the full trial a sample size of 51 patients per arm has been based on a margin positivity of 44%, based on the unit's results, and expected 60% reduction (expected R1 18%) at power 80% (type A error 0.05).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Periadventitial dissection
For the patients randomised for peri-adventitial dissection the right side of the SMA should be completely clear from lymphoneural tissue for at least 180 degrees on right side and from "angle" of the artery to the level of inferior border of the uncinate process.
Periadventitial dissection of the SMA
For the patients randomised for peri-adventitial dissection the right side of the SMA should be completely clear from lymphoneural tissue for at least 180 degrees on right side and from "angle" of the artery to the level of inferior border of the uncinate process. In the presence of an accessory or replaced right hepatic artery the peri-adventitial dissection should also be carried out around this vessel as well.
NO periadventitial dissection
For patients randomised to NO peri-adventitial dissection, the lymphoneural tissue around the SMA should be left intact
No Periadventitial dissection of the SMA
lymphoneural tissue around SMA left intact
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No Periadventitial dissection of the SMA
lymphoneural tissue around SMA left intact
Periadventitial dissection of the SMA
For the patients randomised for peri-adventitial dissection the right side of the SMA should be completely clear from lymphoneural tissue for at least 180 degrees on right side and from "angle" of the artery to the level of inferior border of the uncinate process. In the presence of an accessory or replaced right hepatic artery the peri-adventitial dissection should also be carried out around this vessel as well.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
2. Patients that cannot provide consent
3. All borderline, locally advanced and metastatic pancreatic tumours on imaging (based on NCCN criteria)
4. All patients with a cytological or histological diagnosis of cholangiocarcinoma, ampullary and duodenal carcinoma
5. All patients with benign disease or dysplasia with no evidence of malignancy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital Birmingham NHS Foundation Trust
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nikolaos Chatzizacharias
Consultant HPB Surgeon
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospitals Birmingham NHS Foundation Trust
Birmingham, County (Optional), United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RRK6941
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.